I did research on DCvax-L trial for Glioblastoma Multiforme (GBM) Brain Cancer. Phase III trial study is expecting to have positive encouraging results of its continuing study using DCvax-L to treat patients who are diagnose with brain cancers. The results is some of the patients has live beyond 11 years since being treated with DCvax-L, and many more are living pass 6 years when the life expectancy for patient with brain cancer is 8.6 months. and a total of 14.9 months when treated with chemo. This is very good encouraging news for patients diagnose with brain cancer and the medical field. Patients treated with DCvax-L for brain cancer can live longer lives then they could in the pass.
Dr Linda Liau to present those findings in a conference in London on September 21 and 22. The market might get these results before the London Conference, because of SEC rulings of info must be made public so every one has a fair chance of knowledge about a stock new info. This is the type of news the markets and medical field has been waiting for.
DCvax-L results will help to send Northwest biotherapeutics(NWBO) IPO soaring. Great Job Northwest Biotherapeutics and investors.
Market Data 
Markets 
AI
